marked.bio

Company

Sunshine Lake Pharma

2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker; 1 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Trials

2 of 6 trials shown

  1. HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

    Recruiting Phase 3 Sunshine Lake Pharma Started 2023Primary completion 2027-11 NCT05586074

    Clifutinibcytarabineazacitidinedecitabineidarubicinpegfilgrastimfludarabine

    Subject is positive for FLT3 mutation in bone marrow or whole blood as determined by the central lab

    FLT3 mutation (ITD/TKD)Leukemia, Acute Myeloid (AML)

  2. A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML

    Recruiting Phase 1/2 Sunshine Lake Pharma Started 2022Primary completion 2027-12 NCT05133882

    Clifutinib Besylate

    the extension phase requires the subject to be positive for the FLT3-ITD mutation.

    FLT3 mutation (ITD/TKD)Acute Myeloid Leukemia, Adult